Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCEL OLE: Long-Term Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Phase 2Enrolling by invitation
- Sponsor
- QED Therapeutics
- Start
- Apr 2026
- Primary completion
- May 2036
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of infigratinib in hypochondroplasia (HCH), sponsored by QED Therapeutics. Started Apr 2026; status: enrolling by invitation.
02
Drugs
infigratinib
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT07393373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393373.